| Sonidegib studied in …STUDIED_INderived39 of 39show fewer |
|---|
| → studied in | NCT05669339Phase 2 · recruiting AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma · 39 trials list this drug (4 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04806646Phase 2 · active not recruiting Tailored Sonidegib Schedule After Complete Response in BCC · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04007744Phase 1 · active not recruiting Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors · 39 trials list this drug (4 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04066504completed Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02195973Phase 1 · completed Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer · 39 trials list this drug (4 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03534947Phase 2 · completed A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma · 39 trials list this drug (4 active) | — | — | Malignant Skin Neoplasm,Basal Cell Carcinoma,Invasive Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04402073Phase 2 · terminated Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma · 39 trials list this drug (4 active) | — | — | Medulloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06880848Phase 4 · completed Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China · 39 trials list this drug (4 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07068568completed Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma · 39 trials list this drug (4 active) | — | — | Basal Cell Neoplasm,Basal Cell Carcinoma,Eyelid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05463757recruiting Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study · 39 trials list this drug (4 active) | — | — | Skin Neoplasm,Basal Cell Neoplasm,Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03434262Phase 1 · completed SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors · 39 trials list this drug (4 active) | — | — | Neoplasm,Embryonal Neoplasm,Central Nervous System Embryonal Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02027376Phase 1 · completed Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients · 39 trials list this drug (4 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02086552Phase 2 · completed Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma · 39 trials list this drug (4 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00880308Phase 1 · completed Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma,Medulloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01208831Phase 1 · completed An East Asian Study of LDE225 · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma,Medulloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01576666Phase 1 · completed Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors · 39 trials list this drug (4 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Glioblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769768Phase 1 · completed Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients · 39 trials list this drug (4 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02138929Phase 1 · completed LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma · 39 trials list this drug (4 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787552Phase 1/Phase 2 · completed A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF · 39 trials list this drug (4 active) | — | — | Myeloproliferative Neoplasm,Essential Thrombocythemia,Polycythemia Vera+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01431794Phase 1/Phase 2 · terminated Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma · 39 trials list this drug (4 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01954355Phase 1 · completed LDE225 and Paclitaxel in Solid Tumors · 39 trials list this drug (4 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02129101Phase 1 · completed Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies · 39 trials list this drug (4 active) | — | — | Myelodysplastic Syndrome,Myelodysplastic/Myeloproliferative Neoplasm,Chronic Myelomonocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01327053Phase 2 · completed A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02182622Phase 1 · withdrawn LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel · 39 trials list this drug (4 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111187Phase 1 · completed A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer · 39 trials list this drug (4 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02151864Phase 1 · completed LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis · 39 trials list this drug (4 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02303041Phase 2 · terminated Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma · 39 trials list this drug (4 active) | — | — | Skin Neoplasm,Malignant Skin Neoplasm,Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01708174Phase 2 · completed A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) · 39 trials list this drug (4 active) | — | — | Medulloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01125800Phase 1/Phase 2 · completed A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB · 39 trials list this drug (4 active) | — | — | Hepatoblastoma,Glioma,Medulloblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02254551Phase 2 · terminated Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma · 39 trials list this drug (4 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01529450NA · completed Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01826214Phase 2 · completed Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia · 39 trials list this drug (4 active) | — | — | Acute Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01911416NA · withdrawn A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer · 39 trials list this drug (4 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02002689Phase 2 · terminated LDE225 for Patients With PTCH1 or SMO Mutated Tumors · 39 trials list this drug (4 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00961896Phase 2 · completed A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients · 39 trials list this drug (4 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01033019Phase 2 · terminated To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01350115Phase 2 · completed Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) · 39 trials list this drug (4 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01757327Phase 2 · withdrawn LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer · 39 trials list this drug (4 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01694589early Phase 1 · withdrawn A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer · 39 trials list this drug (4 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |